Targeting classical but not neurogenic inflammation reduces peritumoral oedema in secondary brain tumours

Journal of Neuroimmunology

Volumn 250, Issue 1-2, 2012, Pages 59-65

  Lewis, Kate M ^a   Harford Wright, Elizabeth ^a   Vink, Robert ^a   Ghabriel, Mounir N ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Blood brain barrier; Brain metastases; Cerebral oedema; Dexamethasone; NK1 antagonist; Substance P

Indexed keywords

ALBUMIN; APREPITANT; DEXAMETHASONE SODIUM PHOSPHATE; EVANS BLUE; FOSAPREPITANT; N ACETYLTRYPTOPHAN; SUBSTANCE P;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN EDEMA; BRAIN METASTASIS; BRAIN TUMOR; BRAIN WATER; BRAIN WATER CONTENT; CARCINOGENESIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; EXTRAVASATION; MALE; NEUROGENIC INFLAMMATION; NONHUMAN; PATHOGENESIS; PERITUMORAL EDEMA; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; RAT; SECONDARY BRAIN TUMOR; WATER CONTENT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BLOOD-BRAIN BARRIER; BRAIN EDEMA; BRAIN NEOPLASMS; DEXAMETHASONE; DISEASE MODELS, ANIMAL; INFLAMMATION; MALE; RATS; RATS, WISTAR; RECEPTORS, NEUROKININ-1; SUBSTANCE P;

EID: 84864842674     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2012.06.001     Document Type: Article

References (63)

1. Alpert E., Seigerman C. Steroid withdrawal psychosis in a patient with closed head injury. Arch. Phys. Med. Rehabil. 1986, 67:766-769.
2. Andersen C., Jensen F.T. Differences in blood-tumour-barrier leakage of human intracranial tumours: quantitative monitoring of vasogenic oedema and its response to glucocorticoid treatment. Acta Neurochir. (Wien) 1998, 140:919-924.
3. Andersen C., Astrup J., Gyldensted C. Quantitation of peritumoural oedema and the effect of steroids using NMR-relaxation time imaging and blood-brain barrier analysis. Acta Neurochir. Suppl. (Wien) 1994, 60:413-415.
4. Annunziata P., Cioni C., Santonini R., Paccagnini E. Substance P antagonist blocks leakage and reduces activation of cytokine-stimulated rat brain endothelium. J. Neuroimmunol. 2002, 131:41-49.
5. Ayata C., Ropper A.H. Ischaemic brain oedema. J. Clin. Neurosci. 2002, 9:113-124.
6. Barry C.M., Helps S.C., den Heuvel C., Vink R. Characterizing the role of the neuropeptide substance P in experimental subarachnoid hemorrhage. Brain Res. 2011, 1389:143-151.
7. Betz A.L., Coester H.C. Effect of steroids on edema and sodium uptake of the brain during focal ischemia in rats. Stroke 1990, 21:1199-1204.
8. Budde M.D., Gold E., Jordan E.K., Smith-Brown M., Frank J.A. Phase contrast MRI is an early marker of micrometastatic breast cancer development in the rat brain. NMR Biomed. 2012, 25:726-736.
9. Cifuentes N., Pickren J.W. Metastases from carcinoma of mammary gland: an autopsy study. J. Surg. Oncol. 1979, 11:193-205.
10. Cioni C., Renzi D., Calabro A., Annunziata P. Enhanced secretion of substance P by cytokine-stimulated rat brain endothelium cultures. J. Neuroimmunol. 1998, 84:76-85.
11. Cornford E.M., Young D., Paxton J.W., Finlay G.J., Wilson W.R., Pardridge W.M. Melphalan penetration of the blood-brain barrier via the neutral amino acid transporter in tumor-bearing brain. Cancer Res. 1992, 52:138-143.
12. Donkin J.J., Vink R. Mechanisms of cerebral edema in traumatic brain injury: therapeutic developments. Curr. Opin. Neurol. 2010, 23:293-299.
13. Donkin J.J., Nimmo A.J., Cernak I., Blumbergs P.C., Vink R. Substance P is associated with the development of brain edema and functional deficits after traumatic brain injury. J. Cereb. Blood Flow Metab. 2009, 29:1388-1398.
14. Donkin J.J., Cernak I., Blumbergs P.C., Vink R. A substance P antagonist reduces axonal injury and improves neurologic outcome when administered up to 12hours after traumatic brain injury. J. Neurotrauma 2011, 28:217-224.
15. Engelhorn T., Savaskan N.E., Schwarz M.A., Kreutzer J., Meyer E.P., Hahnen E., Ganslandt O., Dorfler A., Nimsky C., Buchfelder M., Eyupoglu I.Y. Cellular characterization of the peritumoral edema zone in malignant brain tumors. Cancer Sci. 2009, 100:1856-1862.
16. Fast A., Alon M., Weiss S., Zer-Aviv F.R. Avascular necrosis of bone following short-term dexamethasone therapy for brain edema. Case report. J. Neurosurg. 1984, 61:983-985.
17. Forster C., Waschke J., Burek M., Leers J., Drenckhahn D. Glucocorticoid effects on mouse microvascular endothelial barrier permeability are brain specific. J. Physiol. 2006, 573:413-425.
18. Front D., Israel O., Kohn S., Nir I. The blood-tissue barrier of human brain tumors: correlation of scintigraphic and ultrastructural findings: concise communication. J. Nucl. Med. 1984, 25:461-465.
19. Gavrilovic I.T., Posner J.B. Brain metastases: epidemiology and pathophysiology. J. Neurooncol 2005, 75:5-14.
20. Graeber M.B., Li W., Rodriguez M.L. Role of microglia in CNS inflammation. FEBS Lett. 2011, 585:3798-3805.
21. Gu Y.T., Zhang H., Xue Y.X. Dexamethasone enhances adenosine 5'-triphosphate-sensitive potassium channel expression in the blood-brain tumor barrier in a rat brain tumor model. Brain Res. 2007, 1162:1-8.
22. Gu Y.T., Qin L.J., Qin X., Xu F. The molecular mechanism of dexamethasone-mediated effect on the blood-brain tumor barrier permeability in a rat brain tumor model. Neurosci. Lett. 2009, 452:114-118.
23. Guerin C., Wolff J.E., Laterra J., Drewes L.R., Brem H., Goldstein G.W. Vascular differentiation and glucose transporter expression in rat gliomas: effects of steroids. Ann. Neurol. 1992, 31:481-487.
24. Harford-Wright E., Thornton E., Vink R. Angiotensin-converting enzyme (ACE) inhibitors exacerbate histological damage and motor deficits after experimental traumatic brain injury. Neurosci. Lett. 2010, 481:26-29.
25. Hasegawa H., Ushio Y., Hayakawa T., Yamada K., Mogami H. Changes of the blood-brain barrier in experimental metastatic brain tumors. J. Neurosurg. 1983, 59:304-310.
26. Heiss J.D., Papavassiliou E., Merrill M.J., Nieman L., Knightly J.J., Walbridge S., Edwards N.A., Oldfield E.H. Mechanism of dexamethasone suppression of brain tumor-associated vascular permeability in rats. Involvement of the glucocorticoid receptor and vascular permeability factor. J. Clin. Invest. 1996, 98:1400-1408.
27. Helps S.C., Thornton E., Kleinig T.J., Manavis J., Vink R. Automatic nonsubjective estimation of antigen content visualized by immunohistochemistry using color deconvolution. Appl. Immunohistochem. Mol. Morphol. 2012, 20:82-90.
28. Hempen C., Weiss E., Hess C.F. Dexamethasone treatment in patients with brain metastases and primary brain tumors: do the benefits outweigh the side-effects?. Support. Care Cancer 2002, 10:322-328.
29. Jamshidi J., Yoshimine T., Ushio Y., Hayakawa T. Effects of glucocorticoid and chemotherapy on the peritumoral edema and astrocytic reaction in experimental brain tumor. J. Neurooncol 1992, 12:197-204.
30. Jelsma R., Bucy P.C. The treatment of glioblastoma multiforme of the brain. J. Neurosurg. 1967, 27:388-400.
31. Kim H., Lee J.M., Park J.S., Jo S.A., Kim Y.O., Kim C.W., Jo I. Dexamethasone coordinately regulates angiopoietin-1 and VEGF: a mechanism of glucocorticoid-induced stabilization of blood-brain barrier. Biochem. Biophys. Res. Commun. 2008, 372:243-248.
32. Landis S.H., Murray T., Bolden S., Wingo P.A. Cancer statistics, 1998. CA Cancer J. Clin. 1998, 48:6-29.
33. Lesniak M.S., Gabikian P., Tyler B.M., Pardoll D.M., Brem H. Dexamethasone mediated inhibition of local IL-2 immunotherapy is dose dependent in experimental brain tumors. J. Neurooncol 2004, 70:23-28.
34. Li Z.Q., Liang G.B., Xue Y.X., Liu Y.H. Effects of combination treatment of dexamethasone and melatonin on brain injury in intracerebral hemorrhage model in rats. Brain Res. 2009, 1264:98-103.
35. Lu T.S., Avraham H.K., Seng S., Tachado S.D., Koziel H., Makriyannis A., Avraham S. Cannabinoids inhibit HIV-1 Gp120-mediated insults in brain microvascular endothelial cells. J. Immunol. 2008, 181:6406-6416.
36. Marchi N., Angelov L., Masaryk T., Fazio V., Granata T., Hernandez N., Hallene K., Diglaw T., Franic L., Najm I., Janigro D. Seizure-promoting effect of blood-brain barrier disruption. Epilepsia 2007, 48:732-742.
37. McCluskey J., Gutteridge D.H. Avascular necrosis of bone after high doses of dexamethasone during neurosurgery. Br. Med. J. (Clin. Res. Ed) 1982, 284:333-334.
38. McGirt M.J., Chaichana K.L., Gathinji M., Attenello F., Than K., Ruiz A.J., Olivi A., Quinones-Hinojosa A. Persistent outpatient hyperglycemia is independently associated with decreased survival after primary resection of malignant brain astrocytomas. Neurosurgery 2008, 63:286-291. (discussion 291).
39. Moroz M.A., Huang R., Kochetkov T., Shi W., Thaler H., de Stanchina E., Gamez I., Ryan R.P., Blasberg R.G. Comparison of corticotropin-releasing factor, dexamethasone, and temozolomide: treatment efficacy and toxicity in U87 and C6 intracranial gliomas. Clin. Cancer Res. 2011, 17:3282-3292.
40. Morreale V.M., Herman B.H., Der-Minassian V., Palkovits M., Klubes P., Perry D., Csiffary A., Lee A.P. A brain-tumor model utilizing stereotactic implantation of a permanent cannula. J. Neurosurg. 1993, 78:959-965.
41. Mukand J.A., Blackinton D.D., Crincoli M.G., Lee J.J., Santos B.B. Incidence of neurologic deficits and rehabilitation of patients with brain tumors. Am. J. Phys. Med. Rehabil. 2001, 80:346-350.
42. Myers M.J., Scott M.L., Deaver C.M., Farrell D.E., Yancy H.F. Biomarkers of inflammation in cattle determining the effectiveness of anti-inflammatory drugs. J. Vet. Pharmacol. Ther. 2010, 33:1-8.
43. Nakagawa H., Groothuis D.R., Owens E.S., Fenstermacher J.D., Patlak C.S., Blasberg R.G. Dexamethasone effects on [125I] albumin distribution in experimental RG-2 gliomas and adjacent brain. J. Cereb. Blood Flow Metab. 1987, 7:687-701.
44. Nimmo A.J., Vink R. Recent patents in CNS drug discovery: the management of inflammation in the central nervous system. Recent Pat. CNS Drug Discov. 2009, 4:86-95.
45. Nimmo A.J., Cernak I., Heath D.L., Hu X., Bennett C.J., Vink R. Neurogenic inflammation is associated with development of edema and functional deficits following traumatic brain injury in rats. Neuropeptides 2004, 38:40-47.
46. Paemeleire K., de Hemptinne A., Leybaert L. Chemically, mechanically, and hyperosmolarity-induced calcium responses of rat cortical capillary endothelial cells in culture. Exp. Brain Res. 1999, 126:473-481.
47. Palma C., Bigioni M., Irrissuto C., Nardelli F., Maggi C.A., Manzini S. Anti-tumour activity of tachykinin NK1 receptor antagonists on human glioma U373 MG xenograft. Br. J. Cancer 2000, 82:480-487.
48. Posner J.B., Chernik N.L. Intracranial metastases from systemic cancer. Adv. Neurol. 1978, 19:579-592.
49. Shinoura N., Suzuki Y., Yamada R., Tabei Y., Saito K., Yagi K. Relationships between brain tumor and optic tract or calcarine fissure are involved in visual field deficits after surgery for brain tumor. Acta Neurochir. (Wien) 2010, 152:637-642.
50. Shuto T., Matusnaga S., Inomori S., Fujino H. Efficacy of gamma knife surgery for control of peritumoral edema associated with metastatic brain tumors. J. Neurol. Neurosurg. Psychiatry 2008, 79:1061-1065.
51. Sinha S., Bastin M.E., Wardlaw J.M., Armitage P.A., Whittle I.R. Effects of dexamethasone on peritumoural oedematous brain: a DT-MRI study. J. Neurol. Neurosurg. Psychiatry 2004, 75:1632-1635.
52. Song H.T., Jordan E.K., Lewis B.K., Gold E., Liu W., Frank J.A. Quantitative T2* imaging of metastatic human breast cancer to brain in the nude rat at 3T. NMR Biomed. 2011, 24:325-334.
53. Turner R., Vink R. Inhibition of neurogenic inflammation as a novel treatment for ischemic stroke. Timely Top. Med. Cardiovasc. Dis. 2007, 11:E24.
54. Turner R.J., Blumbergs P.C., Sims N.R., Helps S.C., Rodgers K.M., Vink R. Increased substance P immunoreactivity and edema formation following reversible ischemic stroke. Acta Neurochir. Suppl. 2006, 96:263-266.
55. Turner R.J., Helps S.C., Thornton E., Vink R. A substance P antagonist improves outcome when administered 4h after onset of ischaemic stroke. Brain Res. 2011, 1393:84-90.
56. Ushio Y., Chernik N.L., Shapiro W.R., Posner J.B. Metastatic tumor of the brain: development of an experimental model. Ann. Neurol. 1977, 2:20-29.
57. Vink R., Donkin J.J., Cruz M.I., Nimmo A.J., Cernak I. A substance P antagonist increases brain intracellular free magnesium concentration after diffuse traumatic brain injury in rats. J. Am. Coll. Nutr. 2004, 23:538S-540S.
58. Watanabe Y., Asai H., Ishii T., Kiuchi S., Okamoto M., Taniguchi H., Nagasaki M., Saito A. Pharmacological characterization of T-2328, 2-fluoro-4'-methoxy-3'-[[[(2S,3S)-2-phenyl-3-piperidinyl]amino]methyl]-[1, 1'-biphenyl]-4-carbonitrile dihydrochloride, as a brain-penetrating antagonist of tachykinin NK1 receptor. J. Pharmacol. Sci. 2008, 106:121-127.
59. WHO National Cancer Control Programmes: Policies and Managerial Guidelines 2002, World Health Organisation, Geneva, Switzerland. 2nd edition.
60. Woie K., Koller M.E., Heyeraas K.J., Reed R.K. Neurogenic inflammation in rat trachea is accompanied by increased negativity of interstitial fluid pressure. Circ. Res. 1993, 73:839-845.
61. Yamada K., Ushio Y., Hayakawa T., Arita N., Yamada N., Mogami H. Effects of methylprednisolone on peritumoral brain edema. A quantitative autoradiographic study. J. Neurosurg. 1983, 59:612-619.
62. Zhang M., Olsson Y. Hematogenous metastases of the human brain-characteristics of peritumoral brain changes: a review. J. Neurooncol 1997, 35:81-89.
63. Zhang R.D., Price J.E., Fujimaki T., Bucana C.D., Fidler I.J. Differential permeability of the blood-brain barrier in experimental brain metastases produced by human neoplasms implanted into nude mice. Am. J. Pathol. 1992, 141:1115-1124.